The abstract is read at the publisher; the summary is JClub's.
In a French cohort of 2321 adults with cystic fibrosis starting elexacaftor-tezacaftor-ivacaftor, ppFEV 1 declined by 0·70% per year after the initial rise, with about one-third showing persistent decline.
- Why it matters: CF is linked to faster lung function decline without CFTR modulators, but the longer-term rate of ppFEV 1 decline after early ETI improvement is unclear in real-world adults.
- What they did: Adults aged at least 18 years with at least one F508del variant initiating ETI between Dec 24, 2019, and Dec 23, 2023 were followed for 3 years; ppFEV 1 decline was modeled using a linear mixed-effects approach after using the highest ppFEV 1 within 3 months as baseline.
- The result: After a median 14·5 percentage-point increase in the first 3 months, subsequent mean decline was 0·70% per year; 68·2% had no or limited decline (≤1·5%/year) while 31·8% declined >1·5%/year, and azithromycin or inhaled antibiotics at 1 year were linked to lower risk of >1·5%/year decline.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.